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a  b  s  t  r  a  c  t
The  quantification  of  a large  panel  of  endogenous  steroids  in  serum  by  LC–MS/MS  represents  a  pow-
erful  clinical  tool  for  the  screening  or diagnosis  of  diverse  endocrine  disorders.  This  approach  has  also
demonstrated  excellent  sensitivity  for the  detection  of  testosterone  misuse  in the anti-doping  field,  espe-
cially in  female  athlete  population.  In  both  situations,  the  use  of  dried  blood  spots  (DBS)  could  provide
a  viable  alternative  to invasive  venous  blood  collection.  Here,  the  evaluation  of  DBS  sampling  for the
quantification  of  a panel  of  endogenous  steroids  using  UHPLC-MS/MS  is  described.
The  UHPLC-MS/MS  method  was  validated  for  quantitative  analysis  of  eleven  free  and  eight  conjugated
steroids  and was  then  used  for  the  analysis  of  DBS  samples  collected  in  14  healthy  women  during  a
normal menstrual  cycle  (control  phase)  followed  by a  28-days  testosterone  gel  treatment  (treatment
phase).  Results  were  compared  with those  obtained  from  serum  matrix.  Satisfactory  performance  was
obtained  for  all compounds  in terms  of selectivity,  linearity,  accuracy,  precision,  combined  uncertainty,
stability  as well  as  extraction  recovery  and matrix  effects.  In control  phase,  high  correlation  was  observed
between  DBS  and serum  concentrations  for most  compounds.  In treatment  phase,  higher  testosterone
concentrations  were  observed  in  capillary  than  in  venous  DBS,  suggesting  a  possible  interference  resulting
from  testosterone  contamination  on  finger(s)  used  for gel  application.
Steroid profiling  in  capillary  DBS  represents  a  simple  and  efficient  strategy  for  monitoring  endogenous
steroid  concentrations  and  their  fluctuation  in  clinical  context  of  steroid-related  disorders,  or  for  the









The diagnosis and the monitoring of various endocrine condi-
tions frequently depend on the quantitative analysis of endogenous
steroids in blood matrix. For many years, this analysis was  per-
formed using immunoassays allowing high-throughput. However,
this technique is subject to cross-reactivity and often limited to
the measurement of a single or few compounds instead of a flex-
ible panel of substances. Actually, clinical laboratories rather use
liquid chromatography-tandem mass spectrometry (LC–MS/MS)
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s gold standard method to measure steroid hormones, because
t offers the possibility of quantifying multiple analytes at the
ame time with higher specificity and selectivity [1]. Along fur-
her extensions of the panel, e.g. phase II metabolites, LC–MS/MS is
ndeed a valuable approach for the study of potential alterations in
teroidogenesis due to hormonal imbalances, especially in women
or whom androgenic activity is not necessarily reflected by serum
estosterone level [2,3].
In the anti-doping context, testosterone misuse is currently tar-
eted using an individual and longitudinal monitoring of urinary
iomarkers of testosterone in the so-called Athlete Biological Pass-
ort (ABP) [4]. In case of abnormal values for one or several of
hese markers, a time consuming and expensive analysis based
n gas chromatography-combustion- isotope ratio MS  (GC/C/IRMS)
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terone and its metabolites. While the implementation of this tool
improved the testosterone detection capability, various confound-
ing factors may  influence the urinary steroid profile complicating
its interpretation and decreasing its sensitivity [5–7]. Furthermore,
athletes rather resort to low doses of topical testosterone, which
significantly reduces peaks of urinary concentrations that are diffi-
cult to discriminate from natural variability [7–9].
To overcome these limitations, endogenous steroid profiling in
serum has been proposed as a potential complementary approach
to the urinary steroid profile for the detection of testosterone
misuse by athletes [9,10]. Particularly, the blood matrix is more
informative than urine for the correlation between hormone
concentration and the physiological responses. The longitudi-
nal monitoring in serum has been proven particularly useful for
testosterone detection in female subjects in whom menstrual
fluctuations may  lead to a great source of variation for urinary
biomarkers disrupting their sensitivity [7,9,11].
A primary drawback of the application of serum steroid profil-
ing is that it requires invasive venous blood sampling and sample
collection by a trained phlebotomist. Moreover, these biological
specimens have to be transported under cooled temperature con-
ditions within a short timeframe, which all increase the total costs
of sample collection. Dried blood spots (DBS), which are based
on the transfer of a limited volume of capillary blood onto a fil-
ter paper or similar matrix, could tackle these obstacles offering
a convenient and more affordable alternative. This process ben-
efits from minimal invasiveness, simplicity of sample collection,
facilitated transport and storage conditions, and reduced costs that
could allow for more frequent sampling for anti-doping programs.
The advent of volumetric microsampling technologies has further
improved the collection of DBS for quantitative purposes. While
DBS have been used for neonatal screening for decades, its applica-
bility has been recently evaluated for SARS–CoV–2 serology assays
[12], therapeutic drug monitoring [13] or alcohol abstinence [14].
In the anti-doping context, DBS have been considered as comple-
mentary matrix for many years [15–18] and have been investigated
for either direct detection of prohibited substances [19–21] or indi-
rect detection through potential biomarkers [22–24]. In particular,
a method using volumetric microsampling and GC–MS/MS was
recently developed for the quantification of testosterone and eight
synthetic anabolic androgenic steroids (AAS) [25]. However, this
method was limited to the quantification of only one endogenous
AAS (EAAS) and could therefore be hardly applied in the clinical
context for the monitoring of steroidogenesis disorders such as
polycystic ovary syndrome or congenital adrenal hyperplasia.
In this study, we developed a UHPLC-MS/MS method for
the simultaneous determination of eleven free (testosterone,
epitestosterone, androstenedione, dehydroepiandrosterone
(DHEA), 5-dihydrotestosterone (DHT), progesterone,
17-hydroxyprogesterone, cortisol, corticosterone, deoxy-
corticosterone and 11-deoxycortisol) and eight conjugated
(glucuro-conjugated androsterone and etiocholanolone, sulfo-
conjugated testosterone, DHEA, androsterone, etiocholanolone,
epiandrosterone and dehydroandrosterone) steroids in DBS
matrix. Following validation according to World-Anti Doping
Agency (WADA) requirements, the method was applied to the
analysis of DBS samples collected from healthy eumenorrheic
women during a normal menstrual cycle followed by a 28-days T
gel treatment and results were compared with those of serum.
2. Materials and methods2.1. Chemical & reagents
Methanol (MeOH) was purchased from Macron Fine Chem-






Journal of Pharmaceutical and Biomedical Analysis 204 (2021) 114280
99 %) and UPLC grade MeOH from Biosolve BV (Valkenswaard,
he Netherlands) while ammonium hydroxide (NH4OH;  28–30 %)
olution was obtained from Sigma-Aldrich (Buchs, Switzerland).
harcoal Dextran Stripped Human Serum was supplied by Dunn
abortechnick GMbH (Asbach, Germany). Milli Q quality water
as obtained from a Milli-Q® grade system (Millipore, MA,  USA)
nd was used for the preparation of LC mobile phases and extrac-
ion/reconstitution solutions.
Testosterone (T), androstenedione were purchased from
luka (Buchs, Switzerland), 11-deoxycortisol, deoxycorticosterone,
7-hydroxyprogesterone, cortisol, epitestosterone from Sigma-
ldrich (Buchs, Switzerland), dihydrotestosterone, corticosterone,
ehydroepiandrosterone (DHEA) from Chemie Brunschwig (Basel,
witzerland), etiocholanolone glucuronide, androsterone sulfate,
eyhdroepiandrosterone sulfate (DHEAS), testosterone sulfate,
piandrosterone sulfate from Steraloids (Newport, RI, USA),
ndrosterone glucuronide, etiocholanolone sulfate from LGC Stan-
ards (Wesel, Germany) and progesterone from Laboratoire Golaz
Lausanne, Switzerland). Internal labelled standards (IS) were pro-
ided by National Measurement Institute (Pymble, Australia).
.2. Sample preparation
.2.1. Calibration curves and quality control samples
Artificial steroid stripped blood was prepared from whole blood
f a healthy volunteer using a modified method reported by Higashi
t al. [26]. The whole blood sample was  first centrifuged at 1500
 g for 15 min  and the separated plasma was discarded. The red
lood cells (RBCs) were washed with saline solution, centrifuged
nd the supernatant was  discarded. This procedure was  repeated
hree times and the washed RBCs were then combined with char-
oal stripped serum to obtain a hematocrit of 50 %.
Calibration and quality control (QC) samples were then prepared
n artificial blood by spiking with reference material of each analyte
Table S1) and 20 L of the spiked blood was  spotted onto Whatman
03TM protein saver cards (GE Healthcare). The cards were dried
or a minimum of 1 h at room temperature (RT) and stored at 4 ◦C
nless used for stability study.
.2.2. DBS samples extraction
For each sample, the whole spot of 20-L was excised from the
BS card and transferred into a clean 1.5 mL  conical polypropy-
ene microcentrifuge tube. One milliliter of methanol/water 95:5
v/v) containing the internal standard (IS) mixture (Table S2) was
dded to each tube which was then briefly vortexed and subjected
o sonication for 15 min. The supernatant was  transferred into a 96-
ell collection plate equipped with glass inserts and evaporated to
ryness under nitrogen stream. The extracts were finally recon-
tituted in 100 L of a MeOH/H2O (50:50, v/v) solution, and after
0 min  of gentle shaking, 10 L of each extract was injected into
HPLC-MS/MS system.
.3. Instrumentation and analytical conditions
An Acquity UPLC I-class (Waters, Milford, USA) equipped with a
inetex C18 column (150 × 2.1 mm,  1.7 m;  Phenomenex, Tor-
ance, CA, USA) was  used for chromatographic separation. The
obile phase A solution was  H2O + 5 mM  ammonium formate
nd mobile phase B was MeOH + 5 mM ammonium formate.
olumn temperature was set at 60 ◦C and separation was per-
ormed with a flow rate at 300 L/min, applying the same gradient
s described in [27]. MS/MS  analysis was carried out using a
evo-TQ S triple quadrupole mass spectrometer (Waters, Milford,
A,  USA) equipped with an electrospray ionization (ESI) source
perating in polarity switching (positive/negative) mode. Multiple
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ditions described in Table S3. MassLynx software version 4.2 was
used for data acquisition and TargetLynx for data processing.
2.4. Method validation
2.4.1. Selectivity
Selectivity was assessed by the analysis of steroid stripped blood
specimens in ten replicates for the presence of interfering signals
at the expected retention times of the target analytes.
2.4.2. Calibration curve and linearity
Target analytes were spiked at various concentration levels
(Table S1) and calibration curves were established with at least
five concentration levels and prepared in three separate analytical
series. Linear calibration models were generated for each com-
pound (peak area ratio of each steroid to its respective IS) using
a 1/x weighted least-squared regression. The calibration curve was
accepted if the accuracy of back-calculated concentration values
at each level was less than ±15 % (±20 % at the lower limit of
quantification (LLOQ)). The range was considered to be linear if the
determination coefficient was greater than 0.99 and in the absence
of systematic pattern in the residuals.
2.4.3. Bias, precision, uncertainty and LLOQ
To assess the precision and accuracy of the assay, QC fortified
at four concentration levels (LLOQ, Low, Mid, High) of the target
analytes were analyzed in six replicates and on three separate ana-
lytical series. In accordance with the WADA technical document
TD2019DL [28], combined measurement uncertainty (uc) was  also
assessed by quadratic combinations of the intermediate precision
and the root mean square of the bias estimates. A pre-defined
uncertainty acceptance criterion was set at 20 % of the mean result
at each concentration level of the QCs. LLOQ was determined as the
concentration at which uncertainty was below 20 %.
2.4.4. Extraction recovery and matrix effects
Extraction recovery was calculated as the ratio of the peak
areas of the analyte from the pre-extracted spiked and post-
extracted spiked DBS samples prepared in triplicate. Matrix effects
were investigated by comparing the peak areas of the analytes in
post-extracted spiked samples to peak areas of the corresponding
reference standard. For each analyte, the concentration corre-
sponding to the calibration solution 6 was used for these analyses
(Supplemental Table 1).
2.4.5. Stability
DBS samples from a volunteer were collected from finger prick
(20 L onto Whatman 903TM protein saver cards), loaded into a
foil pouch with a silica gel desiccant, and stored at three different
storage conditions (RT, 4 ◦C and−20 ◦C) for 1 and 3 weeks. For each
condition, three spots were used and extracted. The post-extraction
stability of extracts was also investigated after one week of storage
in the autosampler at approximately 10 ◦C.
2.5. Clinical samples description
2.5.1. Testosterone gel study
Fourteen healthy female volunteers participated to an open-
label trial. All subjects provided written informed consent prior to
any study procedures and the trial was approved by the local Ethi-
cal Committee of the Canton de Vaud in Switzerland (2018−02106,
SNCTP000003264) and Swissmedic (2018DR1168), registered on
www.isrctn.com (ISRCTN10122130) and was conducted in accor-
dance with the Declaration of Helsinki as described previously [7].
Briefly, the study was divided into three 4-weeks phases corre-
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eeks. Phase 1 corresponded to the control phase during which
amples were collected once a week. Phase 2 corresponded to the
reatment during which 0.5 g testosterone gel (Tostran® 20 mg/g)
as  self-administered every morning on the upper thigh and/or
bdomen for 28 days. Samples were collected before the appli-
ation of testosterone gel, which corresponded approximately to
4 h post-application, and with the sampling scheme similar to
hase 1. Phase 3 was  similar to phase 1 and corresponded to the
ost-treatment phase.
Serum samples were collected from antecubital vein in 8.5 mL
D Vacutainer® SSTTM II Advance tubes and whole blood in 4 mL
D Vacutainer® K2EDTA tubes. DBS samples were generated either
sing volumetric 10-L microsampling HemaXis DB10 kits (DBS
ystem SA, Gland, Switzerland) from finger-prick and by depositing
0 L of EDTA whole blood onto cards (Whatman 903TM protein
aver cards), which were left to dry for a minimum of 1 h at RT and
tored at 4 ◦C with a desiccant. Hematological variables including
ematocrit (HCT) were measured in whole blood samples using a
ully automated hematology analyzer (Sysmex XN-1000, Sysmex).
For the analysis of DBS generated with HemaXis DB10, two
0-L spots were used for the quantification of steroids with
he method described above. Serum samples were extracted and
nalyzed using a method reported earlier [27] and results were
ompared with those measured in the DBS and corrected with
CT level using the following equation: Corrected concentration
 (DBS concentration)/(1-HCT). Comparison of the steroid concen-
rations obtained with the two methods was  performed using the
assing-Bablok regression and correlations were calculated using
pearman’s correlation method with R Studio software.
.5.2. Comparison between finger prick and Tasso-M20 DBS
To assess the efficiency of the Tasso-M20 push-button blood
ollection device (Tasso Inc, WA,  USA) for the measurement of the
teroid profile, capillary blood was collected from fourteen healthy
olunteers (seven males and seven females) using both finger-
ricks and Tasso-M20 devices positioned on the upper arm. Blood
amples from finger-pricks (20 L) were deposited onto filter paper
Whatman 903TM protein saver cards), left to dry for at least 1 h,
nd then stored at room temperature with desiccant. The dried
asso volumetric 20-L tips samples were stored under ambient
onditions with desiccant until analysis. The tips were analyzed as
escribed previously for the DBS. The correlation between finger-
rick DBS and Tasso-M20 DBS was calculated using Spearman’s
orrelation method with R Studio software.
. Results
.1. Method validation
Quantitative performance of the method and the summary of
alidation results are described in Table 1(complete set of data for
ach QC level are shown in Table S4). Regarding selectivity, no inter-
ering signals were observed for the ten replicates of negative blood
amples at the expected retention times of the analytes, owing to
he adequate chromatographic separation in conjunction with the
wo  structure specific MRM  transitions.
The linearity range was determined for each compound and
he accuracies of the back-calculated concentrations at each cal-
bration level met  the predefined criteria (less than ±15 % and
ess than ±20 % bias at LLOQ). The method demonstrated satisfac-
ory accuracy, expressed in terms of bias, and precision at each QC
evel (Table S4 at each QC concentration). The relative bias did not
xceed 10 % for any QCs. The precision, represented by repeatabil-
ty and intermediate precision, was below 10 % with the exception
f the lowest QC for glucuro-conjugated androsterone and eti-
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Table  1
Summary of validation results. RT: retention time; LLOQ: lower limit of quantification.












Testosterone 9.81 2.6−3.9 2.1−3.3 2.1−4.6 3.6−6.5 0.02−25 20 110 95
Epitestosterone 11.5 2.4−3.8 1.5−3.2 2.6−3.2 4.1−5.2 0.05−10 50 110 99
Androstenedione 8.74 2.5−6.2 1.3−2.3 1.6−3.6 3.5−7.3 0.1−25 100 108 93
DHEA  10.61 2.1−3.6 2.3−2.9 2.6−3.9 3.7−5.7 2.5−150 2500 111 92
DHT  12.04 1.9−2.6 1.8−2.8 1.9−2.8 3.4−4.1 0.25−10 250 115 91
Progesterone 13.42 2.1−4.7 2.1−2.8 2.1−3.2 3.1−6.0 0.025−25 25 112 93
17-
hydroxyprogesterone
10.42 2.2−3.7 1.7−3.1 2.2−3.9 3.4−5.4 0.1−25 100 112 97
Cortisol 5.07 3.5−5.2 1.5−5.0 1.6−5.5 4.7−9.0 1−400 1000 110 97
Corticosterone 6.97 3.5−4.6 1.5−4.9 1.8−4.9 4.7−7.5 0.25−100 250 112 92
Deoxycorticosterone 9.45 2.6−5.9 1.9−2.9 2.4−4.1 4.4−6.6 0.1−10 100 112 92
11-Deoxycortisol 7.36 2.2−3.6 2.2−3.0 2.2−4.5 3.6−6.1 0.1−5 100 110 90
Androsterone
Glucuronide
9.61  3.7−8.6 3.6−7.2 4.8−11.8 6.5−16.0 1−100 1000 67 100
Etiocholanolone
Glucuronide
8.99  3.4−9.6 4.8−13.3 4.8−14.1 6.7−20.4 1−100 1000 74 105
Testosterone Sulfate 5.29 2.8−3.4 2.6−3.6 3.5−3.9 5.0−5.8 0.25−25 250 84 96
Androsterone Sulfate 8.18 2.4−5.6 2.1−3.0 2.8−3.4 4.2−6.9 5−2500 5000 82 95
Etiocholanolone
Sulfate
7.89  2.7−4.8 1.9−3.7 1.9−5.8 4.5−7.8 5−2500 5000 84 90
DHEA  Sulfate 5.95 2.7−6.3 2.3−5.0 2.9−5.8 4.4−8.3 50−10000 50000 82 96

































6.7  4.4−9.4 3.9−8.2 5.0−8.2 
ocholanolone. Nevertheless, at this concentration (1 ng/mL), the
precision was considered acceptable as the results were still below
15 %. Combined uncertainty, representing statistical dispersion of
the values attributed to a measured quantity, was also assessed in
agreement with WADA regulations (TD2019DL), and the estimates
were all below 20 % as a predefined uncertainty acceptance crite-
rion except for the lowest QC of etiocholanolone glucuronide with
an uncertainty estimate of 20.4 %.
Recovery was excellent for all unconjugated steroids (108–115
%), while it demonstrated lower but still acceptable results for sul-
fate (80–84 %) and glucuronide (67–74 %) conjugated metabolites.
No significant matrix effect was observed for any analyte. The carry-
over was negligible with all traces below 0.2 %.
Concerning the stability of the analytes in DBS, no significant
difference was observed between the storage conditions (RT, 4 ◦C
and−20 ◦C) for any steroid, except for progesterone. After 3 weeks
of storage, progesterone level was significantly lower when stored
at −20 ◦C compared to RT (data not shown). Extracts stored in the
autosampler for one week demonstrated similar results to fresh
extracts.
3.2. Analysis of DBS from clinical study
To validate the use of DBS in clinical setting and physiolog-
ical condition, the hematocrit-adjusted concentration measured
in DBS during the control phase (phase 1) of the clinical study
was compared with those measured in serum for each steroid.
Epitestosterone, DHT, deoxycorticosterone, 11-deoxycortisol and
testosterone sulfate were below LLOQ or could not be detected
and were thus not included for the further comparison. Where
the reference could be made to serum concentrations, Passing-
Bablok regression was assessed for each compound and the plots
are presented in Fig. 1. The slope, intercept and their confidence
intervals of 95 % (95 % CI) as well as the correlation coefficient were
evaluated. All compounds demonstrated a correlation coefficient
higher than 0.8 and a slope between 0.69 and 1.13. Exempting
testosterone, androstenedione, cortisol, androsterone sulfate and
etiocholanolone glucuronide, a positive intercept was obtained for
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To further evaluate the use of DBS in the doping context for
he detection of testosterone doping, the samples collected dur-
ng the treatment period (phase 2) and after (phase 3) were also
nalyzed. To avoid any potential interference from testosterone
esidue on the fingers used for gel application, DBS samples gen-
rated with EDTA whole blood were also included and analyzed.
estosterone concentration in capillary DBS exhibited unsatisfac-
ory values in comparison to serum with extremely high values
easured for most samples during and after T gel administra-
ion (Fig. 2A), while testosterone concentration measured in DBS
enerated using whole blood collected in EDTA tubes highly corre-
ated with testosterone concentration in serum (Fig. 2B). Notably,
oth matrices demonstrated a similar trend when mean concen-
rations were plotted longitudinally over the three study phases
Fig. 2C). The other compounds demonstrated similar results to
hase 1 alone (Fig. S1).
.3. Comparison between finger prick and Tasso device DBS
Fourteen individuals were recruited for the comparison
etween regular finger-prick or Tasso-M20 push-button device for
he analysis of steroid concentrations in DBS. All quantified steroids
emonstrated strong correlation between both collection meth-
ds. The results are presented for six free steroids (Fig. 3) and the
omparison for the other compounds are available in Fig. S2.
. Discussion
The method described in this study demonstrated reliable quan-
itative performance for the profiling of a panel of steroids in DBS.
s the chromatographic separation and MS/MS  conditions used
n this study were already optimized for the analysis of serum
amples [27], the emphasis was put on the processing of DBS sam-
les. Based on validation data, combined uncertainty was assessed
or each analyte in compliance with the WADA requirements for
uantitative methods, consisting of the intermediate precision and
ias components. For most compounds, uncertainty was  estimated
elow the predefined acceptance criterion of ±20 %. In the case of
tiocholanolone glucuronide, the combined uncertainty was  20.4 %



























Fig. 1. Passing-Bablok regression plots for steroids quantification in serum vs DBS
identity  line, and the confidence bands for regression are delimitated in grey. R is th
at the lowest QC level, which could be related to the low ionization
efficiency of glucuronide-conjugated species in the negative mode.
Nevertheless, as the result was still very close to the predefined
acceptance criterion, it was considered fit for purpose.
The major challenge when developing a DBS method for steroid
analysis is to reach a sufficient sensitivity for the target compounds
that may  be present in low circulating levels, especially in women,
and to cover large and various ranges of concentration. The sensi-
tivity of this developed method was satisfactory for the majority
of the critical compounds, such as testosterone or progesterone
(Fig. S3). DHT, a potential biomarker of testosterone administration,
was the only compound for which the current sensitivity (LLOQ at
250 pg/mL) may  be inadequate for the analysis of DBS samples of
female athletes, which is in part due to its mass spectrometric prop-
erties. Furthermore, slightly higher uncertainty estimations were
obtained at low concentration for the glucuro-conjugated species,
but as they generally circulate at high concentrations in blood, no
true sensitivity issues were encountered [29]. Finally, the concen-
tration of the steroids panel remained generally stable when stored
for 1–3 weeks either at RT, 4 ◦C or −20 ◦C. It highlights that, con-
trary to serum samples usually used for the steroid profiling, DBS
cards can be transported and/or stored at RT with a minimal risk of
degradation.
To first evaluate the applicability of the developed method in
physiological condition, capillary DBS collected over 4 weeks dur-
ing a clinical study involving healthy eumenorrheic women  were
analyzed and concentration values were compared to correspond-





cted during phase 1. Blue line indicates regression line, red dashed line indicates
elation coefficient and 95 % CI corresponds to the 95 % confidence interval.
r>0.84) was discovered between DBS and serum. Passing-Bablok
egression based on robust, non-parametric model was  used to
valuate analytical methods agreement. The model is based on
he hypothesis that if the 95 % CI for intercept includes value
ero and 95 % CI for slope includes value 1, there is no constant
intercept) nor proportional (slope) difference between the two
ethods. These criteria were met  for testosterone, androstene-
ione, cortisol and all conjugated metabolites (with the exception
f epiandrosterone sulfate). For DHEA, 17−OH-progesterone and
rogesterone, 95 % CI for intercepts did not include 0, indicating
 constant difference between the two  methods. It is mainly due
o higher values measured in DBS at low concentration for these
ompounds, which could be partly explained by better recovery
rom DBS. For epiandrosterone sulfate, although upper limit of 95
 CI for slope was  close to 1 (0.92), the two methods had a slight
roportional difference with higher concentrations measured in
erum. Corticosterone also demonstrated a proportional between
oth methods with consistent higher values in serum suggesting
hat both methods should not be used simultaneously. Overall, we
an conclude that results obtained from both methods were in high
greement and that measured concentrations in DBS can be com-
ared with those of serum for most compounds. These results also
mphasize the necessity to adjust concentration measured in DBS
ith HCT [30]. Furthermore, these samples were stored for morehan one year with desiccant before their analysis underlining the
nalytes’ stability in DBS.
Longitudinal monitoring of testosterone in serum has been
roposed as powerful approach for the detection of testosterone
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Fig. 2. Passing-Bablok regression plots of testosterone concentration values between serum and (A) capillary DBS and (B) EDTA-DBS during the whole study. Blue line
indicates regression line, red dashed line indicate identity line, and the confidence bands for regression are delimitated in grey. R is the correlation coefficient and 95 % CI
corresponds to the 95 % confidence interval. (C) Mean plot of testosterone concentration measured in EDTA-DBS and serum throughout the study. The grey area corresponds
to  the treatment phase and divides the three study phases.
ix freeFig. 3. Correlations between concentration levels of sadministration in women [7]. Therefore, to evaluate the appli-
cability of DBS in the context of anti-doping, DBS samples from
the two following phases (testosterone gel administration – phase






 steroids in finger-prick vs Tasso-M20 DBS samples.essed. Related to the use of topical testosterone formulation, a
revious study showed that considerable amounts of testosterone
60 % after 8 h) remained on the intact skin for several hours
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vehicle [31]. Thus, to avoid any potential interferences from testos-
terone residue on fingers used for gel application, DBS samples
generated with EDTA tubes collected at the same time and rep-
resenting rather systemic testosterone concentration were also
analyzed with the developed method. While testosterone levels
demonstrated high concordance between EDTA-DBS and serum,
capillary DBS displayed some extreme values during and after
testosterone administration. It seemed that the testosterone val-
ues increased as the treatment progressed suggesting a potential
accumulation. Indeed, following its application, the gel dried and
the steroid is absorbed into the stratum corneum, which acts as a
reservoir before slowly releasing testosterone into the circulation
[32]. On the contrary, mean testosterone concentration exhibited
similar results between EDTA-DBS and serum when data were lon-
gitudinally plotted. Furthermore, the other analytes concentrations
demonstrated satisfactory correlation with the serum matrix dur-
ing and after the treatment period. These findings confirm the
hypothesis that testosterone is indeed persisting in the finger skin,
and that the local residual testosterone could interfere and generate
high concentrations in capillary blood when collected with finger
prick. This observation could also partly explain the low bioavail-
ability of testosterone gel formulation. Although this hypothesis
is highly likely, we emphasize that the risk of interpersonal con-
tamination is very low as reported in [31], especially if the site of
application is covered or washed [33]. We  point out that the alco-
holic testosterone gel, which is in contact with the application hand,
remains in the finger skin and generates only locally high capillary
testosterone concentration. Therefore, a high capillary testosterone
concentration in DBS is highly likely to reflect a direct contact with
exogenous testosterone gel. Nevertheless, further studies should be
carried out to confirm this hypothesis by combining testosterone
administration and multiple capillary blood collection sites.
To overcome this potential pitfall, the Tasso-M20 push button
device was also evaluated as alternative collection method. This
device allows collecting capillary blood on the upper arm using
volumetric absorptive microsampling (Fig. S4). We  demonstrated
that steroid concentrations were comparable between finger-prick
DBS and Tasso DBS collected from the fingers and arms of four-
teen individuals, thereby demonstrating the independence from
spot support and sample collection site. While this approach might
be beneficial in this context, it could also generate similar issues
if testosterone gel is administered on the upper arm, at the same
location as the Tasso-M20.
5. Conclusion
In summary, a fit-for-purpose UHPLC-MS/MS method was
developed and validated for the quantification of a panel of steroids
in DBS. This method could be applied to anti-doping as a comple-
mentary approach for the longitudinal monitoring of steroid profile
and detection of testosterone administration in the ABP allowing
for more frequent sampling and for targeting blood (serum) and
urine sample collection that would be used for a full steroid profile
and for confirmatory GC/C/IRMS analysis. The increased sampling
frequency would provide a better estimation of natural baseline
variability of a given athlete and would provide a better resolu-
tion of a possible doping picture [34]. This approach could also
be employed for the monitoring of steroid-related pathologies in
the clinical context. Indeed, for patients requiring regular med-
ical visits or for whom venipuncture is complicated (neonates,
elderly patients), DBS collected with Tasso-M20 or finger prick with
HemaXis DB10 at home or on-site could be a valuable alternative
to classical serum collection.
[
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